Preliminary findings from this ongoing study support the prognostic value of non-VHL mutations includingPBRM1, BAP1, SETD2, KDM5C, ATM, MTOR, andPTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.